medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2019-19-170-175medsovet-5368Research ArticleОнкоурологияOncourologyКлинические исследования эффективности химиотерапии в сочетании с андрогенной депривацией у пациентов с олигометастатическим гормоночувствительным раком предстательной железыClinical studies of chemotherapy efficacy in combination with androgenic deprivation in patients with oligometastatic hormone-sensitive prostate cancerhttps://orcid.org/0000-0002-0567-4616ПоповС. В.PopovS. V.

д.м.н., профессор кафедры общей врачебной практики Медицинского института

117198, Россия, Москва, ул. Миклухо-Маклая, д. 6 

Dr. of Sci. (Med), Professor of the Department of General Medical Practice at the Medical Institute

6, Miklukho-Maklay St., 117198, Moscow, Russia

servit77@yandex.ruРоссийский университет дружбы народовРоссияFederal State Autonomous Educational Institution of Higher Education «Peoples’ Friendship University of Russia»Russian Federation201908122019019170175Copyright © Попов С.В., 20192019Попов С.В.Popov S.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/5368рак предстательной железыгормоночувствительностьолигометастазыандроген-депривационная терапияхимиотерапиядоцетакселэффективностьprostate cancerhormone sensitivityoligometastasesandrogen-deprivational therapychemotherapydocetaxeleffectivenessReferencesКаприн А.Д., Старинский В.В., Петрова Г.В. (ред.). Состояние онкологической помощи населению России в 2018 году. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2019. 236 с. Режим доступа: http://www.oncology.ru/service/statistics/condition/2018.pdf.Kaprin A.D., Starinskiy V.V., Petrova G.V. (eds). State of Cancer Care in Russia in 2018. Moscow: Gertsen P.A. Moscow Cancer Research Institute – filial of TSYB Medical Radiological Research Center of the Ministry of Health of Russia; 2019. 236 с. (In Russ.) Available at: http://www.oncology.ru/service/statistics/condition/2018.pdf.Алексеев Б.Я., Андрианов А.Н., Каприн А.Д. Современные подходы к выбору терапии 1-й линии больных метастатическим гормоночувствительным раком предстательной железы. Онкоурология. 2017;13(4):85-90. doi: 10.17650/1726-9776-2017-13-4-85-90.Alekseev B.Y., Andrianov A.N., Kaprin A.D. Current approaches to selection of the 1st line therapy in patients with metastatic hormone-sensitive prostate cancer. Onkourologiâ = Cancer Urology. 2017;13(4):85-90. (In Russ.) doi: 10.17650/1726-9776-2017-13-4-85-90.Hellman S., Weichselbaum R.R. Oligometastases WRR. Oligometastases. J Clin Oncol. 1995;13:8–10. doi: 10.1200/JCO.1995.13.1.8.Hellman S., Weichselbaum R.R. Oligometastases WRR. Oligometastases. J Clin Oncol. 1995;13:8–10. doi: 10.1200/JCO.1995.13.1.8.Ost P., Jereczek- Fossa B.A., As N.V., Zilli T., Muacevic A., Olivier K. et al. Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: a multi-institutional analysis. Eur Urol. 2016;69:9–12. doi: 10.1016/j.eururo.2015.07.004.Ost P., Jereczek- Fossa B.A., As N.V., Zilli T., Muacevic A., Olivier K. et al. Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: a multi-institutional analysis. Eur Urol. 2016;69:9–12. doi: 10.1016/j.eururo.2015.07.004.Pasqualetti F., Panichi M., Sainato A., Baldaccini D., Cocuzza P., Gonnelli A. et al. Image-guided stereotactic body radiotherapy in metastatic prostate cancer. Anticancer Res. 2018;38:3119–3122. doi: 10.21873/anticanres.12572.Pasqualetti F., Panichi M., Sainato A., Baldaccini D., Cocuzza P., Gonnelli A. et al. Image-guided stereotactic body radiotherapy in metastatic prostate cancer. Anticancer Res. 2018;38:3119–3122. doi: 10.21873/anticanres.12572.Gravis G., Fizazi K., Joly F., Oudard S., Priou F., Esterni B. et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(2):149–158. doi: 10.1016/S1470-2045(12)70560-0.Gravis G., Fizazi K., Joly F., Oudard S., Priou F., Esterni B. et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, openlabel, phase 3 trial. Lancet Oncol. 2013;14(2):149–158. doi: 10.1016/S1470-2045(12)70560-0.Sweeney C.J., Chen Y.H., Carducci M., Liu G., Jarrard D.F., Eisenberger M. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737–746. doi: 10.1056/NEJMoa1503747.Sweeney C.J., Chen Y.H., Carducci M., Liu G., Jarrard D.F., Eisenberger M. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737–746. doi: 10.1056/NEJMoa1503747.James N.D., Sydes M.R., Clarke N.W., Mason M.D., Dearnaley D.P., Spears M.R. et al.; STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163–1177. doi: 10.1016/S0140-6736 (15)01037-5.James N.D., Sydes M.R., Clarke N.W., Mason M.D., Dearnaley D.P., Spears M.R. et al.; STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163–1177. doi: 10.1016/S0140-6736(15)01037-5.Fizazi K., Jenkins C., Tannock I.F. Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra. Ann Oncol. 2015;26(8):1660–1667. doi: 10.1093/annonc/mdv245.Fizazi K., Jenkins C., Tannock I.F. Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra. Ann Oncol. 2015;26(8):1660–1667. doi: 10.1093/annonc/mdv245.Shenoy N., Kohli M. Role of systemic chemotherapy in metastatic hormone-sensitive prostate cancer. Indian J Urol. 2016;32:257-261. doi: 10.4103/0970-1591.191234.Shenoy N., Kohli M. Role of systemic chemotherapy in metastatic hormone-sensitive prostate cancer. Indian J Urol. 2016;32:257-261. doi: 10.4103/0970-1591.191234.Puente J., Grande E., Medina A., Maroto P., Lainez N., Arranz J.A. Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting. Ther Adv Med Oncol. 2017;9(5):307–318. doi: 10.1177/1758834017692779.Puente J., Grande E., Medina A., Maroto P., Lainez N., Arranz J.A. Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting. Ther Adv Med Oncol. 2017;9(5):307–318. doi: 10.1177/1758834017692779.Vale C.L., Burdett S., Rydzewska L.H.M., Albiges L., Clarke N.W., Fisher D., et al., for the STOpCaP Steering Group. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and metaanalyses of aggregate data. Lancet Oncol. 2016;17(2):243–256. doi: 10.1016/S1470-2045(15)00489-1.Vale C.L., Burdett S., Rydzewska L.H.M., Albiges L., Clarke N.W., Fisher D., et al., for the STOpCaP Steering Group. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol. 2016;17(2):243–256. doi: 10.1016/S1470-2045(15)00489-1.Kapoor A. What’s New in Prostate Cancer Research? Highlights of GU-ASCO 2015. Can Urol Assoc J. 2015;9(5-6Suppl3):S148–S153. doi: 10.5489/cuaj.2994.Kapoor A. What’s New in Prostate Cancer Research? Highlights of GU-ASCO 2015. Can Urol Assoc J. 2015;9(5-6Suppl3):S148–S153. doi: 10.5489/cuaj.2994.Botrel T.E.A., Clark O., Pompeo A.C.L., Bretas F.F.H., Sadi M.V., Ferreira U., Borges dos Reis R. Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis. PLoS One. 2016;11(6):e0157660. doi: 10.1371/journal.pone.0157660.Botrel T.E.A., Clark O., Pompeo A.C.L., Bretas F.F.H., Sadi M.V., Ferreira U., Borges dos Reis R. Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis. PLoS One. 2016;11(6):e0157660. doi: 10.1371/journal.pone.0157660.Damodaran S., Kyriakopoulos C.E., Jarrard D.F. Newly diagnosed metastatic prostate cancer – has the paradigm changed? Urol Clin North Am. 2017;44(4):611–621. doi: 10.1016/j.ucl.2017.07.008.Damodaran S., Kyriakopoulos C.E., Jarrard D.F. Newly diagnosed metastatic prostate cancer – has the paradigm changed? Urol Clin North Am. 2017;44(4):611–621. doi: 10.1016/j.ucl.2017.07.008.Kapoor A., Hotte S.J. Androgen receptor axis-targeted agents. Can Urol Assoc J. 2016;10(7-8Suppl3):S146–S148. doi: 10.5489/cuaj.4057.Kapoor A., Hotte S.J. Androgen receptor axis-targeted agents. Can Urol Assoc J. 2016;10(7-8Suppl3):S146–S148. doi: 10.5489/cuaj.4057.Merseburger A.S., Alcaraz A., von Klot C.A. Androgen deprivation therapy as backbone therapy in the management of prostate cancer. Onco Targets Ther. 2016;9:7263–7274. doi: 10.2147/OTT.S117176.Merseburger A.S., Alcaraz A., von Klot C.A. Androgen deprivation therapy as backbone therapy in the management of prostate cancer. Onco Targets Ther. 2016;9:7263–7274. doi: 10.2147/OTT.S117176.Shiota M., Yokomizo A., Eto M. Taxane Chemotherapy for Hormone-Naïve Prostate Cancer with Its Expanding Role as Breakthrough Strategy. Front Oncol. 2015;5:304. doi: 10.3389/fonc.2015.00304.Shiota M., Yokomizo A., Eto M. Taxane Chemotherapy for Hormone-Naïve Prostate Cancer with Its Expanding Role as Breakthrough Strategy. Front Oncol. 2015;5:304. doi: 10.3389/fonc.2015.00304.Chen J., Zhang X., Sun G., Zhao J., Liu J., Zhao P., Dai J., Shen P., Zeng H. The effect of additional chemotherapy on high-risk prostate cancer: a systematic review and meta-analysis. Onco Targets Ther. 2018;11:9061–9070. doi: 10.2147/OTT.S187239.Chen J., Zhang X., Sun G., Zhao J., Liu J., Zhao P., Dai J., Shen P., Zeng H. The effect of additional chemotherapy on high-risk prostate cancer: a systematic review and meta-analysis. Onco Targets Ther. 2018;11:9061–9070. doi: 10.2147/OTT.S187239.Komura K., Sweeney C.J., Inamoto T., Ibuki N., Azuma H., Kantoff P.W. Current treatment strategies for advanced prostate cancer. Int J Urol. 2018;25(3):220–231. doi: 10.1111/iju.13512.Komura K., Sweeney C.J., Inamoto T., Ibuki N., Azuma H., Kantoff P.W. Current treatment strategies for advanced prostate cancer. Int J Urol. 2018;25(3):220–231. doi: 10.1111/iju.13512.Sathianathen N.J., Philippou Y.A., Kuntz G.M., Konety B.R., Gupta S., Lamb A.D., Dahm P. Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer. Cochrane Database Syst Rev. 2018;(10):CD012816. doi: 10.1002/14651858.CD012816.pub2.Sathianathen N.J., Philippou Y.A., Kuntz G.M., Konety B.R., Gupta S., Lamb A.D., Dahm P. Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer. Cochrane Database Syst Rev. 2018;(10):CD012816. doi: 10.1002/14651858.CD012816.pub2.Nader R., Amm J.E., Aragon-Ching J.B. Role of chemotherapy in prostate cancer. Asian J Androl. 2018;20(3):221-229. doi: 10.4103/aja.aja_40_17.Nader R., Amm J.E., Aragon-Ching J.B. Role of chemotherapy in prostate cancer. Asian J Androl. 2018;20(3):221-229. doi: 10.4103/aja.aja_40_17.Gravis G. Systemic treatment for metastatic prostate cancer. Asian J Urol. 2019;6(2):162–168. doi: 10.1016/j.ajur.2019.02.002.Gravis G. Systemic treatment for metastatic prostate cancer. Asian J Urol. 2019;6(2):162–168. doi: 10.1016/j.ajur.2019.02.002.Hurwitz M.D. Chemotherapy and radiation for prostate cancer. Transl Androl Urol. 2018;7(3): 390–398. doi: 10.21037/tau.2018.03.07.Hurwitz M.D. Chemotherapy and radiation for prostate cancer. Transl Androl Urol. 2018;7(3): 390–398. doi: 10.21037/tau.2018.03.07.Miura Y., Horie S. The role of hormone therapy and chemotherapy in oligometastatic prostate cancer. ESMO Open. 2019;4(Suppl 1):e000471. doi: 10.1136/esmoopen-2018-000471.Miura Y., Horie S. The role of hormone therapy and chemotherapy in oligometastatic prostate cancer. ESMO Open. 2019;4(Suppl 1):e000471. doi: 10.1136/esmoopen-2018-000471.Cornford P., Bellmunt J., Bolla M., Briers E., De Santis M., Gross T. et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71:630–642. doi: 10.1016/j.eururo.2016.08.002.Cornford P., Bellmunt J., Bolla M., Briers E., De Santis M., Gross T. et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71:630–642. doi: 10.1016/j.eururo.2016.08.002.Грицкевич А.А., Мишугин С.В., Русаков И.Г. Возможности комбинации доцетаксела с андрогенной депривацией при инициальной терапии гормоночувствительного рака предстательной железы. Медицинский совет. 2017;(6):94-97. doi: 10.21518/2079-701X-2017-6-94-97.Gritskevich A.A., Mishugin S.V., Rusakov I.G. Possibilities of a combination of docetaxel with androgen deprivation in initial therapy of hormonesensitive prostate cancer. Medicinskij sovet = Medical Council. 2017;(6):94-97. (In Russ.) doi: 10.21518/2079-701X-2017-6-94-97.Gravis G., Boher J.M., Joly F., Soulié M., Albiges L., Priou F. et al.; GETUG. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non- castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol. 2016;70:256–62. doi: 10.1016/j.eururo.2015.11.005.Gravis G., Boher J.M., Joly F., Soulié M., Albiges L., Priou F. et al.; GETUG. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non- castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol. 2016;70:256–62. doi: 10.1016/j.eururo.2015.11.005.Kyriakopoulos C.E., Chen Y.H., Carducci M.A., Liu G., Jarrard D.F., Hahn N.M. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. 2018;36:1080–1087. doi: 10.1200/JCO.2017.75.3657.Kyriakopoulos C.E., Chen Y.H., Carducci M.A., Liu G., Jarrard D.F., Hahn N.M. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. 2018;36:1080–1087. doi: 10.1200/JCO.2017.75.3657.Tucci M., Bertaglia V., Vignani F., Buttigliero C., Fiori C., Porpiglia F., Scagliotti G.V., Di Maio M. Addition of docetaxel to androgen deprivation therapy for patients with hormone-sensitive metastatic prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;69:563–573. doi: 10.1016/j.eururo.2015.09.013.Tucci M., Bertaglia V., Vignani F., Buttigliero C., Fiori C., Porpiglia F., Scagliotti G.V., Di Maio M. Addition of docetaxel to androgen deprivation therapy for patients with hormone-sensitive metastatic prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;69:563–573. doi: 10.1016/j.eururo.2015.09.013.

The authors declare that there are no conflicts of interest present.